ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
In good news for pregnant and lactating people, a recent study has shown that messenger RNA–based COVID-19 vaccines induce a robust antibody response in those who get both of the recommended shots (Sci. Transl. Med. 2021, DOI: 10.1126/scitranslmed.abi8631). During pregnancy and lactation, the immune system modifies itself because if it reacts too strongly, the body will reject the growing fetus. But the system also needs to protect against infection and pass immunity to the baby. To understand how these changes in the immune system might alter the effectiveness of COVID-19 vaccines, Andrea Edlow at Harvard Medical School and colleagues monitored the levels of protective antibodies generated after immunization. The scientists found that though pregnant and lactating people made fewer protective antibodies after the first vaccine dose than a control group, the difference disappeared after the second dose. Because antibodies are also transferred via the placenta and human milk, timing vaccination doses during pregnancy could also help protect the baby. In a second study, the researchers also found differences depending on the sex of the fetus (Sci. Transl. Med. 2021, DOI: 10.1126/scitranslmed.abi7428). People carrying male fetuses had fewer antibodies after SARS-CoV-2 infection and passed fewer antibodies across the placenta than those carrying female fetuses.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X